Literature DB >> 1008019

The antiphlogistic, antinociceptive and antipyretic properties of fenclorac.

G W Nuss, R D Smyth, C H Breder, M J Hitchings, G N Mir, N H Reavey-Cantwell.   

Abstract

Fenclorac (a,m-dichloro-p-cyclohexlphenylacetic acid, diethylammonium salt) is a potent nonsteroidal anti-inflammatory agent with significant analgesic and antipyretic activity. Fenclorac had an ED50 of 7.9 mg/kg in the carrageenan paw edema assay and had a duration of action of 18-22 hours. Comparative tests in the carrageenan paw edema assay in the rat indicated that the potency of fenclorac was 13 times that of aspirin, 3.4 times phenylbutazone, 3 times ibuprofen and 0.3 times indomethacin. Fenclorac was less potent than indomethacin, but more potent than phenylbutazone or aspirin in treatment of developing or established adjuvant arthritis. The anti-inflammatory effectiveness of fenclorac did not depend upon the integrity of the adrenopituitary axis and was not affected by the route of administration or sex of the test animal. Fenclorac was 77 times more potent than aspirin and more than twice as potent as indomethacin in reducing fever in rats rendered hyperthermic with brewer's yeast. Fenclorac did not affect normal body temperatures. Fenclorac did not interfere with cellular immune mechanisms as measured by its lack of effectiveness in experimental allergic encephalomyelitis. Antinociceptive testing indicated that fenclorac had peripheral but not central analgesic activity. Fenclorac had an acute oral LD50 in rats and mice of 285 and 430 mg/kg, respectively. The acute gastric lesion UD50 for fenclorac was 7 mg/kg in the fasted rat. Studies using 51Cr-tagged erythrocytes indicated that fenclorac did not produce significant fecal blood loss in the rat at twice the therapeutic ED50 dose for up to 12 days after dosing. Extensive and prolonged fecal blood loss was observed with a corresponding dose of indomethacin for up to nine days after administration. Comparison of the anti-inflammatory pharmacology, Therapeutic Ratio and the data obtained from the 51Cr-fecal blood loss studies indicated that fenclorac was well tolerated after acute or subacute administration to the rat.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1008019     DOI: 10.1007/bf02026097

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  24 in total

1.  Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics.

Authors:  L C HENDERSHOT; J FORSAITH
Journal:  J Pharmacol Exp Ther       Date:  1959-03       Impact factor: 4.030

2.  Screens for anti-inflammatory drugs.

Authors:  M Di Rosa; D A Willoughby
Journal:  J Pharm Pharmacol       Date:  1971-04       Impact factor: 3.765

3.  The pharmacological properties of ibuprofen, an anti-inflammatory, analgesic and antipyretic agent.

Authors:  S S Adams; K F McCullough; J S Nicholson
Journal:  Arch Int Pharmacodyn Ther       Date:  1969-03

4.  Role of the entero-hepatic cycle of indomethacin on its metabolism, distribution in tissues and its excretion by rats, dogs and monkeys.

Authors:  D W Yesair; M Callahan; L Remington; C J Kensler
Journal:  Biochem Pharmacol       Date:  1970-05       Impact factor: 5.858

5.  Enterohepatic circulation of indomethacin and its role in intestinal irritation.

Authors:  D E Duggan; K F Hooke; R M Noll; K C Kwan
Journal:  Biochem Pharmacol       Date:  1975-10-01       Impact factor: 5.858

6.  Inflammation induced by histamine, serotonin, bradykinin and compound 48-80 in the rat: antagonists and mechanisms of action.

Authors:  H M Maling; M E Webster; M A Williams; W Saul; W Anderson
Journal:  J Pharmacol Exp Ther       Date:  1974-11       Impact factor: 4.030

7.  Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects.

Authors:  R Runkel; M Chaplin; G Boost; E Segre; E Forchielli
Journal:  J Pharm Sci       Date:  1972-05       Impact factor: 3.534

8.  A study of adjuvant-induced polyarthritis in the rat with special reference to associated immunological phenomena.

Authors:  L Katz; S J Piliero
Journal:  Ann N Y Acad Sci       Date:  1969-10-09       Impact factor: 5.691

9.  Plasma inflammation units: an objective method for investigating effects of drugs on experimental inflammation.

Authors:  E M Glenn; W M Kooyers
Journal:  Life Sci       Date:  1966-04       Impact factor: 5.037

10.  Metabolism and pharmacokinetics of a new nonsteroid, anti-inflammatory agent, 2-(3-chloro-o-toluidino) nicotinic acid (clonixin) in rats, dogs and monkeys.

Authors:  B Katchen; S Buxbaum; J Meyer; J Ning
Journal:  J Pharmacol Exp Ther       Date:  1973-02       Impact factor: 4.030

View more
  1 in total

1.  The inhibition of prostaglandin synthetase in vivo by nonsteroidal anti-inflammatory agents.

Authors:  P P Mathur; R L Riley; C P Richardson; N H Reavey-Cantwell
Journal:  Agents Actions       Date:  1977-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.